Navigation Links
Common Drug Eases Restless Legs Syndrome
Date:4/29/2009

Lyrica also improves quality of sleep for patients, study finds,,,,

WEDNESDAY, April 29 (HealthDay News) -- Lyrica, a drug used to treat epilepsy, nerve pain, anxiety and fibromyalgia, shows promise in easing the symptoms of restless legs syndrome, a Spanish researcher reports.

Some 5 percent to 10 percent of adults in the United States have restless legs syndrome (RLS), a disorder that causes people to feel a compelling need to move their legs, especially while lying down. The condition can have a substantial impact on sleep, daily activities and quality of life, researchers say.

"This is the first time this drug is being tried for RLS," said Dr. Diego Garcia-Borreguero, director of the Sleep Research Institute in Madrid. "Pregabalin [Lyrica] is an effective drug for the treatment of RLS -- it leads about 60 percent of patients into clinical remission."

The drug improves both the sensation and motor symptoms of RLS, Garcia-Borreguero said.

He also noted that patients taking Lyrica had improved quality of sleep. "Other drugs for RLS had not been able to solve this problem," he said. "They have not been able to improve sleep."

This use of Lyrica is an off-label one, Garcia-Borreguero cautioned.

The findings were to be presented Wednesday at the American Academy of Neurology's annual meeting, in Seattle.

For the study, Garcia-Borreguero randomly assigned 58 people with RLS to Lyrica or a placebo. Sleep studies were performed at the beginning and end of the 12-week trial.

Garcia-Borreguero found that almost 75 percent of patients taking Lyrica had RLS symptoms stop while taking the drug. Among those who continued to have RLS, their symptoms improved by 66 percent. Patients on placebo saw their symptoms worsen by 29 percent.

In addition, those taking Lyrica had better sleep compared with patients taking placebo. Patients on Lyrica had more slow-wave sleep, or deep sleep. They also spent less time in the lighter sleep stages compared with people taking placebo, Garcia-Borreguero said.

RLS presents as an urge to move the legs, often with unpleasant numbness, tingling or burning sensations. These symptoms increase during rest and are partially relieved through activity. Symptoms worsen at night and tend to progress with age.

The study was funded by Pfizer Inc., the maker of Lyrica.

Dr. Carlos Singer, director of the Movement Disorders Center at the University of Miami School of Medicine, thinks Lyrica provides an alternative to other drugs for RLS and may also have fewer side effects.

"You have another weapon to treat RLS," Singer said. "This drug, to the best of my knowledge, has a very safe record," he said. "I would definitely try it with patients."

Singer noted that more studies are needed to see if the drug is still effective for RLS after long-term use.

More information

For more information on restless legs syndrome, visit the U.S. National Institute of Neurological Disorders and Stroke.



SOURCES: Diego Garcia-Borreguero, M.D., director, Sleep Research Institute, Madrid, Spain; Carlos Singer, M.D., professor, neurology, and director, Movement Disorders Center, University of Miami School of Medicine; April 29, 2009, presentation, American Academy of Neurology's annual meeting, Seattle


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Penn Medicine, CHOP researchers demonstrate first common genetic risk factors for autism
2. Mental health problems more common in kids who feel racial discrimination
3. Type of vitamin B1 could treat common cause of blindness
4. Commonly used ulcer drugs may offer treatment potential in Alzheimers disease
5. The Most Common Cause of Hair Loss Is the Least Suspected, Warns Trichology Expert
6. Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo
7. Silent Heart Attacks More Common Than Thought
8. Mayo Clinic-led researchers confirm gene variants associated with the most common adult leukemia
9. All Persons Who Purchased or Acquired the Common Stock of Sunrise Senior Living, Inc. (Sunrise) Between February 26, 2004 and July 28, 2006, Inclusive, and Were Damaged Thereby (The Class)
10. Tianyin Pharmaceutical Co., Inc. Series A Preferred Shareholders Approved Cash Dividend to Common Stockholders
11. Common Industrial Chemicals May Not Boost Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Drug Eases Restless Legs Syndrome
(Date:2/19/2017)... OH (PRWEB) , ... February 19, 2017 , ... Braun ... The JEMS Conference & Exposition, the event will take place February 23-25, 2017 at ... Industries will be in Booth #909 with three new ambulances on display. ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... home healthcare, will join forces with Healthwise ® at HIMSS 2017 ... the industry leader in evidence-based health education, technology and services, will demonstrate a ...
(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom ... impressed with the safety and reliability of the Stannah Stairlift as well as with ... endorsement by Ken Matthews can be heard on News Radio WHP 580 weekdays from ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume 2 ... ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. Great ... pick and choose from hand-crafted trend-setting designs with smooth animations that will add ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... kept pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing ... nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... According to a new market research report "Particle Counters Market ... Contamination Monitoring of Liquids), and End User (Healthcare Industry, Semiconductor Industry) ... expected to reach USD 330.6 Million by 2021 from USD 275.9 ... 2021. Continue Reading ... ...
(Date:2/17/2017)... , Feb. 17, 2017 Theravance ... Biopharma" or the "Company") today announced the presentation ... potent, and orally administered pan-Janus kinase (JAK) inhibitor ... th Congress of the European Crohn,s and ... Company reported further data from its completed Phase ...
(Date:2/17/2017)... -- Research and Markets has announced the addition of the ... their offering. ... separate comprehensive analytics for the US, Canada , ... , and Rest of World. Annual estimates and forecasts are provided ... provided for these markets. Market data and analytics are derived from primary ...
Breaking Medicine Technology: